BioTuesdays

Category - News

Transition Therapeutics
Developments

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...

October 30, 2015
CASI Pharmaceuticals
Markets

HCW assumes coverage of CASI Pharma at buy

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of CASI Pharmaceuticals (NASDAQ:CASI) with a “buy” rating and $3 price target. The stock closed at $1.21 on Wednesday. CASI is a clinical-stage company...

October 29, 2015
novadaq
Developments

Novadaq Q3 revenue climbs 40%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago. Product sales increased by $5.2-million, or 47%, primarily...

October 28, 2015
Avivagen
Developments

Avivagen sets OxC-beta swine trial in Vietnam

Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine. Earlier this year, Avivagen and NIAS...

October 26, 2015
Titan Pharmaceuticals Logo
Developments

Obama to expand MAT in opioid addiction

President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an order giving...

October 22, 2015
Rock Creek Pharmaceuticals Logo
Markets

Maxim starts Rock Creek Pharma at buy

Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday. Rock Creek’s lead product, anatabine citrate...

October 20, 2015
Profound Medical Logo
Developments

Profound Medical presents TULSA-PRO data

Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London. TULSA is a minimally invasive...

October 16, 2015